Global Thyroid Gland Disorder Treatment Market to Witness Growth, Owing to Increase in Awareness Programs: Technavio

Technavio has published a new report on the global thyroid gland disorder treatment market from 2017-2021. (Graphic: Business Wire)

???pagination.previous??? ???pagination.next???

LONDON--()--The global thyroid gland disorder treatment market is expected to grow at a CAGR of more than 3% during the forecast period, according to Technavio’s latest market research.

In this market research report, Technavio covers the market outlook and growth prospects of the global thyroid gland disorder treatment market for 2017-2021. The market is further categorized into two segments based on the type of disorder, which are hypothyroidism and hyperthyroidism.

“Globally, 750 million people suffer from thyroid disorders, among which more than half are undiagnosed. The major players in the market are introducing innovative and improved formulations and drugs using new drug-delivery technologies. The quick and easy delivery routes used by new formulations along with increased awareness are expected to increase patient compliance, thereby, fostering the market growth during the forecast period,” says Sapna Jha, a lead cardiovascular and metabolic disorders research expert from Technavio.

Technavio’s healthcare and life sciences research analysts segment the global thyroid gland disorder treatment market into the following regions:

  • Americas
  • EMEA
  • APAC

Thyroid gland disorder treatment in the Americas

The thyroid gland disorders treatment market in the Americas is growing at a moderate pace as compared to the global market, owing to the introduction of natural extracts drugs. Associations such as American Thyroid Association (ATA) and Human Growth Foundation are involved in spreading awareness about the disorder and the available treatment options. For instance, American Association of Clinical Endocrinologists (AACE) has initiated a campaign to increase public awareness about the thyroid disorder and educate the Americans about the treatment.

Request a sample report: http://www.technavio.com/request-a-sample?report=57206

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Thyroid gland disorder treatment market in EMEA

EMEA is emerging and facing challenges regarding regulatory guidelines such as rigorous analytical data to compare similarity with the approved products. However, the thyroid gland disorder treatment market in EMEA is expected to benefit from the growing incidence of hypothyroidism in key regions such as Europe.

“The rising number of individuals with hypothyroid, and increasing thyroid awareness programs contribute to this growth,” says Sapna.

For instance, in 2016, Merck Sharp & Dohme collaborated with Thyroid Federation International (TFI) for a campaign called Catching the butterflies, which detects the symptoms of thyroid disorders in children.

Thyroid gland disorder treatment market in APAC

APAC is expected to grow at a higher rate compared to EMEA and the Americas, due to the growing awareness programs through various companies. For instance, in 2015, Abbott collaborated with Indian Thyroid Society (ITS) to spread thyroid awareness in coastal Andhra Pradesh in India. The data estimated from these awareness programs suggests that one in 10 adults in India suffer from hypothyroidism, and the disease ranked ninth among other common ailments such as depression, asthma, cholesterol problem, diabetes, insomnia, and heart problems.

The top vendors in the global thyroid gland disorder treatment market as highlighted in this market research analysis are:

  • Abbott
  • AbbVie
  • Allergan
  • Merck Sharp& Dohme
  • Pfizer
  • RLC LABS

Browse Related Reports:

Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like cardiovascular devices, central nervous system, and in-vitro diagnostics. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.

About Technavio

Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com

Release Summary

The global thyroid gland disorder treatment market is expected to grow at a CAGR of more than 3% during the forecast period, according to Technavio’s latest market research.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com